(Hyperlinks to references in text)

[1]         Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893–917. doi:10.1002/ijc.25516.

[2]         Hall SF, Groome PA, Irish J, O’Sullivan B. TNM-based stage groupings in head and neck cancer: application in cancer of the hypopharynx. Head Neck 2009;31:1–8. doi:10.1002/hed.20917.

[3]         Groome P a, Schulze KM, Mackillop WJ, Grice B, Goh C, Cummings BJ, et al. A comparison of published head and neck stage groupings in carcinomas of the tonsillar region. Cancer 2001;92:1484–94.

[4]         Groome P a, Schulze K, Boysen M, Hall SF, Mackillop WJ, O’Sullivan B, et al. A comparison of published head and neck stage groupings in laryngeal cancer using data from two countries. J Clin Epidemiol 2002;55:533–44.

[5]         Groome PA, Schulze K, Boysen M, Hall SF, Mackillop WJ. A comparison of published head and neck stage groupings in carcinomas of the oral cavity. Head Neck 2001;23:613–24.

[6]         De Jong MC, Pramana J, Knegjens JL, Balm AJM, van den Brekel MWM, Hauptmann M, et al. HPV and high-risk gene expression profiles predict response to chemoradiotherapy in head and neck cancer, independent of clinical factors. Radiother Oncol 2010;95:365–70. doi:10.1016/j.radonc.2010.02.001.

[7]         Janssen HL, Haustermans KM, Balm a J, Begg a C. Hypoxia in head and neck cancer: how much, how important? Head Neck 2005;27:622–38. doi:10.1002/hed.20223.

[8]         Bristow RG, Hill RP. Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 2008;8:180–92. doi:10.1038/nrc2344.

[9]         Wright EA, Howard-Flanders P. The influence of oxygen on the radiosensitivity of mammalian tissues. Acta Radiol 1957;48:26–32.

[10]      Howard-Flanders P, Moore D. The time interval after pulsed irradiation within which injury to bacteria can be modified by dissolved oxygen. I. A search for an effect of oxygen 0.02 second after pulsed irradiation. Radiat Res 1958;9:422–37.

[11]      Tinganelli W, Ma N-Y, Von Neubeck C, Maier A, Schicker C, Kraft-Weyrather W, et al. Influence of acute hypoxia and radiation quality on cell survival. J Radiat Res 2013;54 Suppl 1:i23–30. doi:10.1093/jrr/rrt065.

[12]      Gray LH, Conger AD, Ebert M, Hornsey S, Scott OCA. The Concentration of Oxygen Dissolved in Tissues at the Time of Irradiation as a Factor in Radiotherapy. Br J Radiol 1953;26:638–48.

[13]      Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, et al. Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 2011;12:353–60. doi:10.1016/S1470-2045(11)70061-4.

[14]      Overgaard J. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – A systematic review and meta-analysis. Radiother Oncol 2011;100:22–32. doi:10.1016/j.radonc.2011.03.004.

[15]      Toustrup K, Sørensen BS, Nordsmark M, Busk M, Wiuf C, Alsner J, et al. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. Cancer Res 2011;71:5923–31. doi:10.1158/0008-5472.CAN-11-1182.

[16]      Rademakers SE, Hoogsteen IJ, Rijken PF, Oosterwijk E, Terhaard CH, Doornaert P a, et al. Pattern of CAIX expression is prognostic for outcome and predicts response to ARCON in patients with laryngeal cancer treated in a phase III randomized trial. Radiother Oncol 2013;108:517–22. doi:10.1016/j.radonc.2013.04.022.

[17]      Nordsmark M, Bentzen SM, Rudat V, Brizel D, Lartigau E, Stadler P, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005;77:18–24. doi:10.1016/j.radonc.2005.06.038.

[18]      Brizel DM, Sibley GS, Prosnitz LR, Scher RL, Dewhirst MW, Ph D. TUMOR HYPOXIA ADVERSELY AFFECTS THE PROGNOSIS OF CARCINOMA OF THE HEAD AND NECK. Int J Radiat Oncol • Biol • Phys 1997;38:285–9.

[19]      Nordsmark M, Overgaard J. A confirmatory prognostic study on oxygenation status and loco-regional control in advanced head and neck squamous cell carcinoma treated by radiation therapy. Radiother Oncol 2000;57:39–43.

[20]      Nordsmark M, Overgaard M, Overgaard J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother Oncol 1996;41:31–9.

[21]      Kaanders JH a M, Wijffels KIEM, Marres H a M, Ljungkvist ASE, Pop L a M, Van den Hoogen FJ a, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002;62:7066–74.

[22]      Schrijvers ML, van der Laan BF a M, de Bock GH, Pattje WJ, Mastik MF, Menkema L, et al. Overexpression of intrinsic hypoxia markers HIF1alpha and CA-IX predict for local recurrence in stage T1-T2 glottic laryngeal carcinoma treated with radiotherapy. Int J Radiat Oncol Biol Phys 2008;72:161–9. doi:10.1016/j.ijrobp.2008.05.025.

[23]      Koukourakis MI, Giatromanolaki Al, SIvridis Ef, SImopoulos Co, TUrley He, TAlks K, et al. Hypoxia-inducible factor (HIF1A and HIF2A), angiogenesis, and chemoradiotherapy outcome of squamous cell head-and-neck cancer. Int J Radiat Oncol • Biol • Phys 2002;53:1192–202.

[24]      Aebersold DM, Burri P, Beer KT, Laissue J, Djonov V, Greiner RH, et al. Expression of Hypoxia-inducible Factor-1alpha: A Novel Predictive and Prognostic Parameter in the Radiotherapy of Oropharyngeal Cancer. Cancer Res 2001;61:2911–6.

[25]      Koukourakis MI, Giatromanolaki A, Sivridis E, Simopoulos K, Pastorek J, Wykoff CC, et al. Hypoxia-regulated Carbonic Anhydrase-9 ( CA9 ) Relates to Poor Vascularization and Resistance of Squamous Cell Head and Neck Cancer to Chemoradiotherapy. Clin Cancer Res 2001;7:3399–403.

[26]      De Schutter H, Landuyt W, Verbeken E, Goethals L, Hermans R, Nuyts S. The prognostic value of the hypoxia markers CA IX and GLUT 1 and the cytokines VEGF and IL 6 in head and neck squamous cell carcinoma treated by radiotherapy +/- chemotherapy. BMC Cancer 2005;5:42. doi:10.1186/1471-2407-5-42.

[27]      Panek R, Welsh L, Dunlop A, Wong KH, Riddell AM, Koh D-M, et al. Repeatability and sensitivity of T2* measurements in patients with head and neck squamous cell carcinoma at 3T. J Magn Reson Imaging 2016:Epub ahead of print. doi:10.1002/jmri.25134.

[28]      Fleming IN, Manavaki R, Blower PJ, West C, Williams KJ, Harris a L, et al. Imaging tumour hypoxia with positron emission tomography. Br J Cancer 2014;112:238–50. doi:10.1038/bjc.2014.610.

[29]      Winter SC, Buffa FM, Silva P, Miller C, Valentine HR, Turley H, et al. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. Cancer Res 2007;67:3441–9. doi:10.1158/0008-5472.CAN-06-3322.

[30]      Buffa FM, Harris a L, West CM, Miller CJ. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. Br J Cancer 2010;102:428–35. doi:10.1038/sj.bjc.6605450.

[31]      Eustace A, Mani N, Span PN, Irlam JJ, Taylor J, Betts GNJ, et al. A 26-Gene Hypoxia Signature Predicts Benefit from Hypoxia-Modifying Therapy in Laryngeal Cancer but Not Bladder Cancer. Clin Cancer Res 2013;19:4879–88. doi:10.1158/1078-0432.CCR-13-0542.

[32]      Koukourakis MI, Bentzen SM, Giatromanolaki A, Wilson GD, Daley FM, Saunders MI, et al. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J Clin Oncol 2006;24:727–35. doi:10.1200/JCO.2005.02.7474.

[33]      Rademakers SE, Lok J, van der Kogel AJ, Bussink J, Kaanders JH a M. Metabolic markers in relation to hypoxia; staining patterns and colocalization of pimonidazole, HIF-1α, CAIX, LDH-5, GLUT-1, MCT1 and MCT4. BMC Cancer 2011;11:167. doi:10.1186/1471-2407-11-167.

[34]      Thomson D, Yang H, Baines H, Miles E, Bolton S, West C, et al. NIMRAD – a phase III trial to investigate the use of nimorazole hypoxia modification with intensity-modulated radiotherapy in head and neck cancer. Clin Oncol 2014;26:344–7. doi:10.1016/j.clon.2014.03.003.

[35]      Chung CH, Parker JS, Karaca G, Wu J, Funkhouser WK, Moore D, et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell 2004;5:489–500.

[36]      Chi J-T, Wang Z, Nuyten DS a, Rodriguez EH, Schaner ME, Salim A, et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med 2006;3:e47. doi:10.1371/journal.pmed.0030047.

[37]      Seigneuric R, Starmans MHW, Fung G, Krishnapuram B, Nuyten DS a, van Erk A, et al. Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 2007;83:374–82. doi:10.1016/j.radonc.2007.05.002.

[38]      Pramana J, Van den Brekel MWM, van Velthuysen M-LF, Wessels LF a, Nuyten DS, Hofland I, et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol • Biol • Phys 2007;69:1544–52. doi:10.1016/j.ijrobp.2007.08.032.

[39]      De Jong MC, Pramana J, van der Wal JE, Lacko M, Peutz-Kootstra CJ, de Jong JM, et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010;16:5329–38. doi:10.1158/1078-0432.CCR-10-0799.

[40]      De Jong MC, Ten Hoeve JJ, Grénman R, Wessels LF, Kerkhoven R, Te Riele H, et al. Pretreatment microRNA Expression Impacting on Epithelial-to-Mesenchymal Transition Predicts Intrinsic Radiosensitivity in Head and Neck Cancer Cell Lines and Patients. Clin Cancer Res 2015;21:1–10. doi:10.1158/1078-0432.CCR-15-0454.

[41]      Roepman P, Kemmeren P, Wessels LF a, Slootweg PJ, Holstege FCP. Multiple robust signatures for detecting lymph node metastasis in head and neck cancer. Cancer Res 2006;66:2361–6. doi:10.1158/0008-5472.CAN-05-3960.

[42]      Lendahl U, Lee KL, Yang H, Poellinger L. Generating specificity and diversity in the transcriptional response to hypoxia. Nat Rev Genet 2009;10:821–32. doi:10.1038/nrg2665.

[43]      Bayer C, Shi K, Astner ST, Maftei C-A, Vaupel P. Acute Versus Chronic Hypoxia: Why a Simplified Classification is Simply Not Enough. Int J Radiat Oncol 2011;80:965–8. doi:10.1016/j.ijrobp.2011.02.049.

[44]      Bayer C, Vaupel P. Acute versus chronic hypoxia in tumors. Strahlentherapie Und Onkol 2012;188:616–27. doi:10.1007/s00066-012-0085-4.

[45]      Janssen HLK, Haustermans KMG, Sprong D, Blommestijn G, Hofland I, Hoebers FJ, et al. HIF-1α, pimonidazole, and iododeoxyuridine to estimate hypoxia and perfusion in human head-and-neck tumors. Int J Radiat Oncol Biol Phys 2002;54:1537–49. doi:10.1016/S0360-3016(02)03935-4.

[46]      Maftei C -a., Bayer C, Shi K, Vaupel P. Intra- and intertumor heterogeneities in total, chronic, and acute hypoxia in xenografted squamous cell carcinomas. Strahlentherapie Und Onkol 2012;188:606–15. doi:10.1007/s00066-012-0105-4.

[47]      Wijffels KI, Kaanders JH, Rijken PF, Bussink J, van den Hoogen FJ, Marres H a, et al. Vascular architecture and hypoxic profiles in human head and neck squamous cell carcinomas. Br J Cancer 2000;83:674–83. doi:10.1054/bjoc.2000.1325.

[48]      Brown JM. Evidence for acutely hypoxic cells in mouse tumours, and a possible mechanism of reoxygenation. Br J Radiol 1979;52:650–6.

[49]      Chan N, Koritzinsky M, Zhao H, Bindra R, Glazer PM, Powell S, et al. Chronic Hypoxia Decreases Synthesis of Homologous Recombination Proteins to Offset Chemoresistance and Radioresistance. Cancer Res 2008;68:605–14. doi:10.1158/0008-5472.CAN-07-5472.